MICHELLE BACHTOLD: Open Payments
NPI 1245475607 · CENTREVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 24 payments from 14 companies in 2025. Trend: 2023 $714 · 2024 $588 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 3 | $184 |
| Janssen Biotech, Inc. | 1 | $124 |
| Novo Nordisk Inc | 1 | $102 |
| Ethicon US, LLC | 1 | $94 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $93 |
| Madrigal Pharmaceuticals | 2 | $69 |
| GENZYME CORPORATION | 2 | $64 |
| ABBVIE INC. | 3 | $63 |
| Ardelyx, Inc. | 2 | $37 |
| Celltrion USA Inc. | 1 | $29 |
Products named: TREMFYA, Livdelzi, Wegovy, LINX REFLUX MANAGEMENT SYSTEM, XIFAXAN, DUPIXENT, REZDIFFRA, IBSRELA.
Industry payments across VA — which companies pay providers there.
